Clinical Trial Update: Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update evaluating Paxlovid and Remdesivir to prevent long-term cardiovascular outcomes in people with post-acute sequelae of SARS-CoV-2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• PAXLOVID (Nirmatrelvir and ritonavir)
• Remdesivir (remdesivir)

Snippet

Sponsor: Mount Sinai Hospital, Canada | Conditions: SARS CoV-2 Post-Acute Sequelae | Phase 4 | Status: RECRUITING